Literature DB >> 9850063

Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma.

T E Reichert1, R Day, E M Wagner, T L Whiteside.   

Abstract

Immunohistology for expression of the CD3zeta and CD3epsilon chains in TIL was performed in 138 paraffin-embedded primary oral squamous cell carcinoma tissues and 10 nontumor, inflammatory lesions. Semiquantitative analysis of the staining intensity for zeta chain expression and number of zeta chain expression-positive cells distinguished tumors with absent or low zeta expression (42 of 132) from those with normal zeta expression (90 of 132). Zeta chain expression was inversely correlated with the tumor stage. Survival was significantly lower in patients whose TIL had absent or low zeta expression, controlling for stage (P = 0.003) and lymph node status (P = 0.0005). The prognostic value of zeta chain was restricted to patients with stage III or IV tumors (P = 0.003). The data indicate that absent or decreased zeta expression in TIL combined with tumor stage or nodal status defines a group of patients with oral squamous cell carcinoma who have an extremely poor prognosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9850063

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

1.  Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model.

Authors:  Katherine A Waugh; Sonia M Leach; Brandon L Moore; Tullia C Bruno; Jonathan D Buhrman; Jill E Slansky
Journal:  J Immunol       Date:  2016-07-01       Impact factor: 5.422

2.  JAK3 Variant, Immune Signatures, DNA Methylation, and Social Determinants Linked to Survival Racial Disparities in Head and Neck Cancer Patients.

Authors:  Rafael Guerrero-Preston; Fahcina Lawson; Sebastian Rodriguez-Torres; Maartje G Noordhuis; Francesca Pirini; Laura Manuel; Blanca L Valle; Tal Hadar; Bianca Rivera; Oluwasina Folawiyo; Adriana Baez; Luigi Marchionni; Wayne M Koch; William H Westra; Young J Kim; James R Eshleman; David Sidransky
Journal:  Cancer Prev Res (Phila)       Date:  2019-02-18

3.  Augmentation of T-cell immune responses and signal transduction proteins in oral cancer patients: potential for IL-2-mediated immunotherapy.

Authors:  Vino T Cheriyan; Cessal Thomas; Prabha Balaram
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-02       Impact factor: 4.553

4.  Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?

Authors:  Thomas E Ichim; Boris Minev; Todd Braciak; Brandon Luna; Ron Hunninghake; Nina A Mikirova; James A Jackson; Michael J Gonzalez; Jorge R Miranda-Massari; Doru T Alexandrescu; Constantin A Dasanu; Vladimir Bogin; Janis Ancans; R Brian Stevens; Boris Markosian; James Koropatnick; Chien-Shing Chen; Neil H Riordan
Journal:  J Transl Med       Date:  2011-03-04       Impact factor: 5.531

Review 5.  Alleviating oxidative stress in cancer immunotherapy: a role for histamine?

Authors:  K Hellstrand; M Brune; C Dahlgren; M Hansson; S Hermodsson; P Lindnér; U H Mellqvist; P Naredi
Journal:  Med Oncol       Date:  2000-11       Impact factor: 3.064

Review 6.  Cancer immunoediting from immune surveillance to immune escape.

Authors:  Ryungsa Kim; Manabu Emi; Kazuaki Tanabe
Journal:  Immunology       Date:  2007-03-26       Impact factor: 7.397

7.  Immune reconstitution after autologous hematopoietic transplantation with Lin-, CD34+, Thy-1lo selected or intact stem cell products.

Authors:  Rakesh K Singh; Michelle L Varney; Cheryl Leutzinger; Julie M Vose; Philip J Bierman; Suleyman Buyukberber; Kazuhiko Ino; Kevin Loh; Craig Nichols; David Inwards; Robert Rifkin; James E Talmadge
Journal:  Int Immunopharmacol       Date:  2007-04-20       Impact factor: 4.932

8.  Covert operations: cancer's many subversive tactics in overcoming host defenses.

Authors:  Dan L Longo
Journal:  Trans Am Clin Climatol Assoc       Date:  2013

Review 9.  The tumor microenvironment and its role in promoting tumor growth.

Authors:  T L Whiteside
Journal:  Oncogene       Date:  2008-10-06       Impact factor: 9.867

10.  Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress.

Authors:  Giovanni Mantovani; Antonio Macciò; Clelia Madeddu; Loredana Mura; Giulia Gramignano; Maria Rita Lusso; Elena Massa; Miria Mocci; Roberto Serpe
Journal:  J Mol Med (Berl)       Date:  2003-08-19       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.